4 completed, 1 withdrawn. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Withdrawn 1 |
Follow vaniprevir: new trials by email Literature Review of vaniprevir trials Research Report on vaniprevir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN) vaniprevir (MK7009), Comparator: vaniprevir (MK7009), Comparator: Pegylated Interferon (peg-IFN) alfa-2a - Chronic Genotype 1 Hepatitis C Virus Infection | Phase 2 | Withdrawn | Merck Sharp & Dohme LLC | 2010-11-01 | 2015-10-22 | |
| A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028) Vaniprevir 600 mg b.i.d., Vaniprevir 300 mg b.i.d., Pegylated interferon - Hepatitis C, Chronic | Phase 2 | Completed | Merck Sharp & Dohme LLC | 45 | 2009-10-23 | 2021-02-08 |
| A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016) Vaniprevir, Pegylated Interferon (peg-IFN), Ribavirin - Hepatitis C | Phase 2 | Completed | Merck Sharp & Dohme LLC | 90 | 2009-04-20 | 2018-10-09 |
| Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009) Vaniprevir, Pegylated Interferon (Peg-IFN), Ribavirin (RBV) - Hepatitis C, Chronic | Phase 2 | Completed | Merck Sharp & Dohme LLC | 285 | 2009-03-27 | 2018-10-09 |
| Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007) Comparator: Vaniprevir, Comparator: Pegylated-Interferon (Peg-IFN), Comparator: Ribavirin - Hepatitis C | Phase 2 | Completed | Merck Sharp & Dohme LLC | 95 | 2008-07-25 | 2018-10-09 |
Hepatitis C (4) · Hepatitis C, Chronic (2)
PMID 22473713, PMID 23439259, PMID 23747481, PMID 24120953, PMID 25115901
2009 (1)